News

No change in residual viremia after switch to 2-drug regimen.

In the ASPIRE trial patients on antiretroviral therapy (ART) with three drugs and suppressed viremia were randomized to continue their present ART or to switch to a combination of dolutegravir and lamivudine. Read more

Impact of sustained virologic response (SVR) on mortality in patients with advanced liver disease.

The impact of achieving SVR on all-cause mortality and the incidence of hepatocellular carcinoma (HCC) was evaluated in a cohort of more than 15,000 patients with advanced liver disease in the Veterans Administrations Clinical case registry for hepatitis C. Read... Läs mer

Magazine